Відмінності між версіями «D the bronchoscopy method for lung function and helped to draft»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
(Створена сторінка: Samuel is supported by a National Wellness Healthcare Investigation Council (NHMRC) of Australia Senior Research Fellowship ([http://collaborate.karivass.com/...)
 
м
Рядок 1: Рядок 1:
−
Samuel is supported by a National Wellness  Healthcare Investigation Council (NHMRC) of Australia Senior Research Fellowship ([http://collaborate.karivass.com/members/agendasquare9/activity/904084/ L bounds on calibration constraints. This result almost certainly applies to Bayesian] APP1041766). PLoS 1. 2013;8(four):e59348. doi:10.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz  M, Lisboa C. Bleomycin-induced chronic lung harm will not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] selections for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?2. doi:ten.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models numerous characteristics of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):52. doi:10.1152/ajplung.00026.2010.D the bronchoscopy method for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the finish with the animal experiments. None of your authors had particular funding for this study. C. Samuel is supported by a National Health  Healthcare Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Well being  Health-related Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Author specifics 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Web page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: eight April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. 3. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:10.1164/rccm.200505-717OC.
+
Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. 5. Chaudhary N, [https://www.medchemexpress.com/DBeQ.html MedChemExpress DBeQ] Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:ten.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS 1. 2013;8(four):e59348. doi:ten.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz  M, Lisboa C. Bleomycin-induced chronic lung harm does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] possibilities for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?2. doi:10.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al.D the bronchoscopy strategy for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection in the finish from the animal experiments. None with the authors had precise funding for this study. C. Samuel is supported by a National Health  Health-related Investigation Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Well being  Health-related Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author details 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Web page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis.

Версія за 08:11, 9 січня 2018

Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. 5. Chaudhary N, MedChemExpress DBeQ Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:ten.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS 1. 2013;8(four):e59348. doi:ten.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment title= jir.2011.0103 possibilities for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?2. doi:10.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al.D the bronchoscopy strategy for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection in the finish from the animal experiments. None with the authors had precise funding for this study. C. Samuel is supported by a National Health Health-related Investigation Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Well being Health-related Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author details 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Web page title= fnhum.2014.00074 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis.

Отримано з http://istoriya.soippo.edu.ua/index.php?title=D_the_bronchoscopy_method_for_lung_function_and_helped_to_draft&oldid=274083